CDKN2A and neoplasm: Inactivating mutations and deletions of 3 tumour suppressor loci, namely CDKN2A/B, NF2, and BAP1 predominate, with functional loss of each tumour suppressor occurring in over 50% of cases and single or combinatorial loss of the 3 loci found in all possible permutations (Bueno et al., 2016; Hmeljak et al., 2018; Nastase et al., 2021; Mangiante et al., 2023).